A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis

  1. Jiménez-Morales, A.
  2. Cáliz, R.
  3. Aceituno, S.
  4. Prades, M.
  5. Blanch, C.
Aldizkaria:
Reumatologia Clinica

ISSN: 1885-1398 1699-258X

Argitalpen urtea: 2021

Alea: 17

Zenbakia: 9

Orrialdeak: 536-542

Mota: Artikulua

DOI: 10.1016/J.REUMA.2020.05.004 GOOGLE SCHOLAR